search
Back to results

A Study of AK112 in Advanced Malignant Tumors

Primary Purpose

Advanced Malignant Tumors

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
AK112
AK117
Chemotherapy
Sponsored by
Akeso
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Malignant Tumors

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18 to 75 years old.
  2. Have a life expectancy of at least 3 months.
  3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  4. Phase Ib:Histologically or cytologically confirmed advanced solid tumor.
  5. Phase II:

    cohort 1 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic gastric or GEJ adenocarcinoma.

    cohort 2 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic Biliary Tract Cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer.

    cohort 3 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic pancreatic ductal adenocarcinoma.

  6. Have at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator.
  7. Has adequate organ function.

Exclusion Criteria:

  1. Undergone major surgery within 30 days prior to the first dose of study treatment.
  2. Active central nervous system (CNS) metastases.
  3. History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e.,corticosteroids or immunosuppressive drugs).
  4. Active Hepatitis B or Hepatitis C.
  5. Received previous immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity.
  6. History of severe bleeding tendency or coagulation disorder.

Sites / Locations

  • Zhejiang Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Phase Ib

Phase II

Arm Description

Subjects receive AK112 plus AK117 until progression

AK112 + chemotherapy± AK117 until progression

Outcomes

Primary Outcome Measures

Number of patients with Adverse Events (AEs)
Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs
Objective Response Rate (ORR)

Secondary Outcome Measures

Disease control rate (DCR)
Duration of Response (DOR)
Time to response (TTR)
Progression free survival (PFS)
Overall survival (OS)

Full Information

First Posted
January 14, 2022
Last Updated
January 27, 2022
Sponsor
Akeso
search

1. Study Identification

Unique Protocol Identification Number
NCT05214482
Brief Title
A Study of AK112 in Advanced Malignant Tumors
Official Title
A Phase Ib/II Study of AK112(PD-1 / VEGF Bispecific Antibody) in Combination With AK117(Anti-CD47 Antibody)With or Without Chemotherapy in Advanced Malignant Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 25, 2022 (Actual)
Primary Completion Date
January 25, 2023 (Anticipated)
Study Completion Date
January 25, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Akeso

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Malignant Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase Ib
Arm Type
Experimental
Arm Description
Subjects receive AK112 plus AK117 until progression
Arm Title
Phase II
Arm Type
Experimental
Arm Description
AK112 + chemotherapy± AK117 until progression
Intervention Type
Drug
Intervention Name(s)
AK112
Intervention Description
IV infusion,Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
AK117
Intervention Description
IV infusion,Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
Chemotherapy
Intervention Description
IV infusion,Specified dose on specified days
Primary Outcome Measure Information:
Title
Number of patients with Adverse Events (AEs)
Description
Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs
Time Frame
Up to approximately 2 years
Title
Objective Response Rate (ORR)
Time Frame
Up to approximately 2 years
Secondary Outcome Measure Information:
Title
Disease control rate (DCR)
Time Frame
Up to approximately 2 years
Title
Duration of Response (DOR)
Time Frame
Up to approximately 2 years
Title
Time to response (TTR)
Time Frame
Up to approximately 2 years
Title
Progression free survival (PFS)
Time Frame
Up to approximately 2 years
Title
Overall survival (OS)
Time Frame
Up to approximately 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 to 75 years old. Have a life expectancy of at least 3 months. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Phase Ib:Histologically or cytologically confirmed advanced solid tumor. Phase II: cohort 1 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic gastric or GEJ adenocarcinoma. cohort 2 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic Biliary Tract Cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer. cohort 3 : Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic pancreatic ductal adenocarcinoma. Have at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator. Has adequate organ function. Exclusion Criteria: Undergone major surgery within 30 days prior to the first dose of study treatment. Active central nervous system (CNS) metastases. History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e.,corticosteroids or immunosuppressive drugs). Active Hepatitis B or Hepatitis C. Received previous immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity. History of severe bleeding tendency or coagulation disorder.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weifeng Song, MD
Phone
+86(0760)89873999
Email
clinicaltrials@akesobio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jieer Ying, MD
Organizational Affiliation
Zhejiang Cancer Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jieer Ying, MD
Phone
13858195803
Email
hzyingjieer@163.com

12. IPD Sharing Statement

Learn more about this trial

A Study of AK112 in Advanced Malignant Tumors

We'll reach out to this number within 24 hrs